Charlotte Fenioux1,2, Luis Teixeira3, Slim Fourati1,4, Giovanna Melica1,5, Jean Daniel Lelievre1,5, Sebastien Gallien1,5, Gérard Zalcman6, Jean Michel Pawlotsky1,4, Christophe Tournigand1,2. 1. University Paris Est Créteil, INSERM U955, IMRB, Créteil, France. 2. AP-HP, Hôpital Henri Mondor, Service d'oncologie médicale, Créteil, France. 3. University de Paris, AP-HP, Hôpital Saint-Louis, Breast Disease Center, INSERM U976, Paris, France. 4. AP-HP, Hôpital Henri Mondor, Service de virologie, Créteil, France. 5. AP-HP, Hôpital Henri Mondor, Service d'immunologie clinique et maladies infectieuses, Créteil, France. 6. Université de Paris, AP-HP, Hôpital Bichat-Claude Bernard, Service d'oncologie thoracique and CIC INSERM 1425, Paris, France.
Abstract
IMPORTANCE: Patients with solid cancer are more susceptible to develop SARS-CoV-2 infection and severe complications; the immunogenicity in patients treated with anticancer agents remains unknown. OBJECTIVE: To assess the immune humoral response to 2 or 3 doses of the BNT162b2 (BioNTech; Pfizer) vaccine in patients treated with anticancer agents. DESIGN, SETTING, AND PARTICIPANTS: A prospective observational cohort study was conducted between February 1 and May 31, 2021. Adults treated with anticancer agents who received 2 or 3 doses of vaccine were included; of these, individuals with a weak humoral response 1 month after the second dose received a third injection. INTERVENTIONS: Quantitative serologic testing of antibodies specific for SARS-CoV-2 was conducted before vaccination and during follow-up. MAIN OUTCOMES AND MEASURES: Humoral response was evaluated with a threshold of anti-SARS-CoV-2 spike protein antibody levels at 1000 arbitrary units (AU)/mL to neutralize less-sensitive COVID-19 variants. RESULTS: Among 163 patients (median [range] age, 66 [27-89] years, 86 men [53%]) with solid tumors who received 2 or 3 doses of vaccine, 122 individuals (75%) were treated with chemotherapy, 15 with immunotherapy (9%), and 26 with targeted therapies (16%). The proportions of patients with an anti-S immunoglobulin G titer greater than 1000 AU/mL were 15% (22 of 145) at the time of the second vaccination and 65% (92 of 142) 28 days after the second vaccination. Humoral response decreased 3 months after the second dose. Treatment type was associated with humoral response; in particular, time between vaccine and chemotherapy did not interfere with the humoral response. Among 36 patients receiving a third dose of vaccine, a serologic response greater than 1000 AU/mL occurred in 27 individuals (75%). CONCLUSIONS AND RELEVANCE: The results of this cohort study appear to support the use of a third vaccine dose among patients with active cancer treatment for solid tumors.
IMPORTANCE: Patients with solid cancer are more susceptible to develop SARS-CoV-2 infection and severe complications; the immunogenicity in patients treated with anticancer agents remains unknown. OBJECTIVE: To assess the immune humoral response to 2 or 3 doses of the BNT162b2 (BioNTech; Pfizer) vaccine in patients treated with anticancer agents. DESIGN, SETTING, AND PARTICIPANTS: A prospective observational cohort study was conducted between February 1 and May 31, 2021. Adults treated with anticancer agents who received 2 or 3 doses of vaccine were included; of these, individuals with a weak humoral response 1 month after the second dose received a third injection. INTERVENTIONS: Quantitative serologic testing of antibodies specific for SARS-CoV-2 was conducted before vaccination and during follow-up. MAIN OUTCOMES AND MEASURES: Humoral response was evaluated with a threshold of anti-SARS-CoV-2 spike protein antibody levels at 1000 arbitrary units (AU)/mL to neutralize less-sensitive COVID-19 variants. RESULTS: Among 163 patients (median [range] age, 66 [27-89] years, 86 men [53%]) with solid tumors who received 2 or 3 doses of vaccine, 122 individuals (75%) were treated with chemotherapy, 15 with immunotherapy (9%), and 26 with targeted therapies (16%). The proportions of patients with an anti-S immunoglobulin G titer greater than 1000 AU/mL were 15% (22 of 145) at the time of the second vaccination and 65% (92 of 142) 28 days after the second vaccination. Humoral response decreased 3 months after the second dose. Treatment type was associated with humoral response; in particular, time between vaccine and chemotherapy did not interfere with the humoral response. Among 36 patients receiving a third dose of vaccine, a serologic response greater than 1000 AU/mL occurred in 27 individuals (75%). CONCLUSIONS AND RELEVANCE: The results of this cohort study appear to support the use of a third vaccine dose among patients with active cancer treatment for solid tumors.
Authors: David Tougeron; Maxime Hentzien; Barbara Seitz-Polski; Firouze Bani-Sadr; Jean Bourhis; Michel Ducreux; Sébastien Gaujoux; Philippe Gorphe; Boris Guiu; Khê Hoang-Xuan; Florence Huguet; Thierry Lecomte; Astrid Lièvre; Christophe Louvet; Léon Maggiori; Laura Mansi; Pascale Mariani; Pierre Michel; Amélie Servettaz; Juliette Thariat; Virgine Westeel; Thomas Aparicio; Jean-Yves Blay; Olivier Bouché Journal: Eur J Cancer Date: 2021-04-01 Impact factor: 9.162
Authors: Nassim Kamar; Florence Abravanel; Olivier Marion; Chloé Couat; Jacques Izopet; Arnaud Del Bello Journal: N Engl J Med Date: 2021-06-23 Impact factor: 91.245
Authors: Teresa Lambe; Andrew J Pollard; Merryn Voysey; Shuo Feng; Daniel J Phillips; Thomas White; Homesh Sayal; Parvinder K Aley; Sagida Bibi; Christina Dold; Michelle Fuskova; Sarah C Gilbert; Ian Hirsch; Holly E Humphries; Brett Jepson; Elizabeth J Kelly; Emma Plested; Kathryn Shoemaker; Kelly M Thomas; Johan Vekemans; Tonya L Villafana Journal: Nat Med Date: 2021-09-29 Impact factor: 53.440
Authors: Sherin Juliet Rouhani; Jovian Yu; Daniel Olson; Yuanyuan Zha; Apameh Pezeshk; Alexandra Cabanov; Athalia R Pyzer; Jonathan Trujillo; Benjamin A Derman; Peter O'Donnell; Andrzej Jakubowiak; Hedy L Kindler; Christine Bestvina; Thomas F Gajewski Journal: J Immunother Cancer Date: 2022-06 Impact factor: 12.469
Authors: Aaron Shengting Mai; Ainsley Ryan Yan Bin Lee; Ryan Yong Kiat Tay; Lauren Shapiro; Astha Thakkar; Balazs Halmos; Albert Grinshpun; Yair Herishanu; Ohad Benjamini; Tamar Tadmor; Rachna T Shroff; Bonnie J LaFleur; Deepta Bhattacharya; Siyu Peng; Jeremy Tey; Soo Chin Lee; Louis Yi Ann Chai; Yu Yang Soon; Raghav Sundar; Matilda Xinwei Lee Journal: Eur J Cancer Date: 2022-06-03 Impact factor: 10.002
Authors: V Di Noia; F Pimpinelli; D Renna; M T Maccallini; L Gariazzo; F Riva; E Sperandio; D Giannarelli; F Cognetti Journal: Ann Oncol Date: 2022-02-22 Impact factor: 51.769
Authors: F Nelli; D Giannarelli; A Fabbri; M A Silvestri; J R Giron Berrios; A Virtuoso; E Marrucci; M Schirripa; M Mazzotta; A Onorato; V Panichi; G Topini; G Pessina; F Natoni; C Signorelli; M G Chilelli; F Primi; E M Ruggeri Journal: Ann Oncol Date: 2022-04-09 Impact factor: 51.769
Authors: Marta Sisteré-Oró; Diana D J Wortmann; Naína Andrade; Andres Aguilar; Clara Mayo de Las Casas; Florencia Garcia Casabal; Susana Torres; Eduardo Bona Salinas; Laura Raventos Soler; Andrea Arcas; Carlos Esparre; Beatriz Garcia; Joselyn Valarezo; Rafael Rosell; Roberto Güerri-Fernandez; Maria Gonzalez-Cao; Andreas Meyerhans Journal: Front Immunol Date: 2022-07-05 Impact factor: 8.786